U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C45H63N13O12S2
Molecular Weight 1042.192
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORNIPRESSIN

SMILES

NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)NCC(N)=O

InChI

InChIKey=MUNMIGOEDGHVLE-LGYYRGKSSA-N
InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1

HIDE SMILES / InChI

Description

Ornipressin (ornithine-8-vasopressin, POR-8), is a synthetic vasopressin analogue. Ornipressin produces vasoconstriction via vasopressin V1A receptor-mediated vascular smooth muscle cell contraction. Ornipressin is used to control bleeding in surgical practice. It was introduced in 1971, and approved for use in Germany, Switzerland, New Zealand and Australia.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
9.16 null [pEC50]
8.12 null [pEC50]
9.35 null [pEC50]
7.15 null [pEC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
POR-8

PubMed

Sample Use Guides

In Vivo Use Guide
POR-8 FERRING® (Ornipressin) should be diluted before use. Usually 5 I.U. (1 ampoule) is diluted in 30 mL of physiological saline. No data are available on the compatibility or stability of POR-8 FERRING® when mixed with local anaesthetic solution. The diluted solution is administered by regional infiltration at the operation site. The maximum permitted total dose for tissue infiltration is 5 I.U., due to the possibility of systemic absorption. For gynaecological surgery and laparotomies, more dilute solutions, e.g. 5 I.U. in 50 or 60 mL physiological saline are used. For ENT surgery, somewhat more concentrated solutions, 5 I.U. in 20 mL physiological saline may be required. Extemporaneous dilutions of POR-8 FERRING® should be used on the day on which they are prepared.
Route of Administration: Topical
In Vitro Use Guide
Unknown